@article{e45c04e167fb43f9a1b190babf762532,
title = "Diagnosis of Progressive Multiple Sclerosis from the Imaging Perspective: A Review",
abstract = "Importance: Although magnetic resonance imaging (MRI) is useful for monitoring disease dissemination in space and over time and excluding multiple sclerosis (MS) mimics, there has been less application of MRI to progressive MS, including diagnosing primary progressive (PP) MS and identifying patients with relapsing-remitting (RR) MS who are at risk of developing secondary progressive (SP) MS. This review addresses clinical application of MRI for both diagnosis and prognosis of progressive MS. Observations: Although nonspecific, some spinal cord imaging features (diffuse abnormalities and lesions involving gray matter [GM] and ≥2 white matter columns) are typical of PPMS. In patients with PPMS and those with relapse-onset MS, location of lesions in critical central nervous system regions (spinal cord, infratentorial regions, and GM) and MRI-detected high inflammatory activity in the first years after diagnosis are risk factors for long-term disability and future progressive disease course. These measures are evaluable in clinical practice. In patients with established MS, GM involvement and neurodegeneration are associated with accelerated clinical worsening. Subpial demyelination and slowly expanding lesions are novel indicators of progressive MS. Conclusions and Relevance: Diagnosis of PPMS is more challenging than diagnosis of RRMS. No qualitative clinical, immunological, histopathological, or neuroimaging features differentiate PPMS and SPMS; both are characterized by imaging findings reflecting neurodegeneration and are also impacted by aging and comorbidities. Unmet diagnostic needs include identification of MRI markers capable of distinguishing PPMS from RRMS and predicting the evolution of RRMS to SPMS. Integration of multiple parameters will likely be essential to achieve these aims..",
author = "Massimo Filippi and Paolo Preziosa and Frederik Barkhof and Chard, {Declan T.} and {De Stefano}, Nicola and Fox, {Robert J.} and Claudio Gasperini and Ludwig Kappos and Xavier Montalban and Bastiaan Moraal and Reich, {Daniel S.} and {\`A}lex Rovira and Toosy, {Ahmed T.} and Anthony Traboulsee and Weinshenker, {Brian G.} and Burcu Zeydan and Banwell, {Brenda L.} and Rocca, {Maria A.}",
note = "Funding Information: reported being editor in chief of the Journal of Neurology; receiving compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries; and receiving research support from ARiSLA (Fondazione Italiana di Ricerca per la SLA), Biogen Idec, Fondazione Italiana Sclerosi Multipla, Italian Ministry of Health, Merck Serono, Novartis, Roche, and Teva Pharmaceutical Industries. Dr Preziosa reported receiving speaker honoraria from Biogen Idec, EXCEMED. Merck Serono, and Novartis. Dr Barkhof reported acting as a consultant to Apitope Ltd, Bayer, Biogen Idec, Genzyme, Janssen, Merck, Novartis, and Roche and receiving sponsorship from Biogen, EU-FP7, EU-H2020, Nederlands Wetenschappelijk Onderzoek, Novartis, SMSR, and Teva. Dr Chard reported receiving within the last 3 years honoraria from EXCEMED for faculty-led education work, being a consultant for Biogen and Hoffmann-La Roche, and receiving research funding from the International Progressive MS Alliance, the MS Society, and the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre. Dr De Stefano reported serving as a consultant for Immunic Therapeutics, Merck Serono SA, Novartis Pharma AG, Roche, Sanofi-Genzyme, and Teva and receiving support for congress participation or speaker honoraria from Biogen Idec, Merck Serono, Novartis Pharma AG, Roche, Sanofi-Genzyme, and Teva. Dr Fox reported receiving personal consulting fees from Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis, Sanofi, Teva, and TG Therapeutics; serving on clinical trial advisory committees for Actelion, Biogen, Immunic, and Novartis; and receiving clinical trial contract and research grant funding from Biogen and Novartis. Dr Gasperini reported receiving fees as an invited speaker or travel expenses for attending meetings from Biogen, Genzyme, Merck Serono, Novartis, Sanofi, and Teva. Dr Kappos reported that his institution (University Hospital Basel) has received the following support used exclusively for research support at the departments: steering committee, advisory board, and consultancy fees from Actelion, Alkermes, Almirall, Bayer, Biogen, Celgene/Receptos, df-mp, EXCEMED, GeNeuro SA, Genzyme, Japan Tobacco, Merck, Minoryx, Mitsubishi Pharma, Novartis, Roche, Sanofi, Santhera, and Teva as well as license fees for Neurostatus-UHB products, and reported that the research of the MS Centre in Basel has been supported by grants from Bayer, Biogen, the European Union, Inno-Swiss, Novartis, the Roche Research Foundations, the Swiss MS Society, and the Swiss National Research Foundation. Dr Montalban reported receiving a speaker honorarium and travel expenses for participation in scientific meetings or advisory boards in past years from Actelion, Alexion, Bayer, Biogen, Celgene, EMD Serono, EXCEMED, Genzyme, Medday, Merck, Multiple Sclerosis International Federation, Nervgen, National MS Society, Novartis, Roche, Sanofi-Genzyme, Teva Pharmaceutical Industries, and TG Therapeutics. Dr Reich reported receiving unrelated research funding from Vertex Pharmaceuticals and being supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke. Dr Rovira reported receiving speaker honoraria from Bayer, Biogen, Bracco, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva Pharmaceutical Industries and serving on scientific advisory boards for Bayer, Biogen, Neurodiem, Novartis, Olea Medical, Roche, Sanofi-Genzyme, and SyntheticMR. Dr Toosy reported receiving speaker honoraria from Bayer, Biomedia, and Sereno Symposia International Foundation; receiving meeting expenses from Biogen Idec; and being the United Kingdom principal investigator for 2 clinical trials sponsored by MedDay Pharma. Dr Traboulsee reported receiving research funding from Biogen, Chugai, Genzyme, Novartis, and Roche and receiving consultancy honoraria from Biogen, Genzyme, Roche, Serono, and Teva. Dr Weinshenker reported receiving personal fees from Alexion, Chugai, MedImmune, Mitsubishi-Tanabe, Novartis, and Roche and having a patent of Neuromyelitis optica–immunoglobulin G for diagnosis of neuromyelitis optica with royalties paid to Hospices Civil de Lyon, MVZ Labor PD Dr Volkmann und Kollegen GbR, Oxford University, and RSR Limited. Dr Zeydan reported receiving funding from the National Institutes of Health. Dr Banwell reported serving as a centralized magnetic resonance imaging reviewer for Novartis and serving as an unpaid adviser regarding a pediatric multiple sclerosis clinical trial design for Biogen Idec, Novartis, and Teva Neuroscience. Dr Rocca reported receiving speaker honoraria from Bayer, Biogen Idec, Celgene, Genzyme, Merck Serono, Novartis, Roche, and Teva and receiving research support from the Fondazione Italiana Sclerosi Multipla, Italian Ministry of Health, and MS Society of Canada. No other disclosures were reported. Funding Information: of the “Diagnosis of Progressive MS: The Imaging Perspective” workshop; November 25-26, 2019; Milan, Italy (chaired by Dr Filippi). The workshop was supported by an unrestricted education grant from Merck Serono. Dr Barkhof is supported by the NIHR Biomedical Research Centre at UCLH. Dr Reich is supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke, National Institutes of Health. Dr Toosy is supported by a Medical Research Council grant. Publisher Copyright: {\textcopyright} 2021 American Medical Association. All rights reserved.",
year = "2021",
month = mar,
doi = "10.1001/jamaneurol.2020.4689",
language = "English (US)",
volume = "78",
pages = "351--364",
journal = "JAMA neurology",
issn = "2168-6149",
publisher = "American Medical Association",
number = "3",
}